Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.
SynAct Pharma has reported further analysis of the Phase IIb ADVANCE study (testing resomelagon in rheumatoid arthritis), providing a clearer explanation for the unexpectedly strong placebo response. Management estimates that around 20% of patients entered...
SynAct’s Q226 results marked a strategically important period in defining resomelagon’s clinical and commercial opportunity. Following June’s Phase IIb ADVANCE data, we expect RA to remain the principal value driver, with ACR20, CRP and SDAI signals ...
SynAct Pharma reported Q226 operating expenses of SEK24.6m, down 19% y-o-y, while the net loss narrowed to SEK22.0m and quarter-end cash stood at SEK14.2m. Post-period, the company secured a new financing facility of up to SEK100m from Fenja Capital,...
SynAct Pharma has signed a term sheet with established Brazilian pharmaceutical company Hipolabor for the co-development and commercialisation of resomelagon for dengue and other viral infections in Brazil. We view this agreement positively, as it builds...
SynAct Pharma has reported that some early preclinical data have shown that resomelagon may reduce inflammation and joint damage associated with osteoarthritis, and, hence, may reduce pain and improve quality of life for this patient population. While...
SynAct has reported top-line results from its Phase IIb ADVANCE study evaluating resomelagon in newly diagnosed, treatment-naïve patients with rheumatoid arthritis. In our view, the readout presents an encouraging dataset despite the study not achieving...